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Cost-effectiveness of rotavirus vaccination in the
Netherlands; the results of a consensus model
Mark H Rozenbaum1,5*, Marie-Josee J Mangen2, Carlo Giaquinto3, Jan C Wilschut4, Eelko Hak1, Maarten J Postma1
and for Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group)
Abstract
Background: Each year rotavirus gastroenteritis results in thousands of paediatric hospitalisations and primary care
visits in the Netherlands. While two vaccines against rotavirus are registered, routine immunisation of infants has
not yet been implemented. Existing cost-effectiveness studies showed inconsistent results for these vaccines
because of lack of consensus on the impact. We aimed to investigate which factors had a major impact on cost-
effectiveness and were primarily responsible for the large differences in previously estimated cost-effectiveness
ratios.
Methods: Based on updated data on health outcomes and cost estimates, we re-assessed the cost-effectiveness of
routine paediatric rotavirus vaccination within the National Immunization Program for the Netherlands. Two
consensus meetings were organised with national and international experts in the field to achieve consensus and
resolve potential controversies.
Results: It was estimated that rotavirus vaccination in the Netherlands could avert 34,214 cases of rotavirus
gastroenteritis in children aged less than 5 years. Notably, 2,779 hospitalisations were averted of which 315 were
extensions of existing hospital stays due to nosocomial rotavirus infection. With a threshold varying from 20K€ -
50K€ per QALY and according to the base-case scenario, the full vaccination costs per child leading to cost-
effectiveness was €57.76 -€77.71. Results were sensitive to the inclusion of potential vaccine induced herd
protection, QALY losses and number of deaths associated with rotavirus gastroenteritis.
Conclusions: Our economic analysis indicates that inclusion of rotavirus vaccination in the Dutch National
Immunization Program might be cost-effective depending on the cost of the vaccine and the impact of rotavirus
gastroenteritis on children’s quality of life.
Background
In 2008, approximately 8.8 million children died before
reaching their fifth birthday worldwide [1]. After pneu-
monia, diarrhoea is the second leading cause of mortal-
ity in these children with approximately 1.4 million
deaths annually of which approximately 500,000 are due
to rotavirus (RV) infection [1-3]. While in Western
countries mortality due to diarrhoea is low, a high level
of morbidity has led scientific societies (ESPID and ESP-
GHAN) to recommend the introduction of universal
mass vaccination with rotavirus vaccines to all Western
European infants and children [4,5]. One of the factors
influencing the decision to introduce a new vaccine for
infants, such as the RV vaccine, into the Dutch National
Immunization Program (NIP) involves an acceptable
cost-effectiveness profile under current standards [6].
Over the last few years, four different studies were
performed to assess the cost-effectiveness of routine
infant RV vaccination in the Netherlands, and reported
inconsistent and varying results [7-10]. For example,
Goossens et al. concluded that mass vaccination against
rotavirus gastroenteritis (RVGE) can be attractive from
both an economic and a health care point of view, while
a more recent paper by Mangen et al. stated that vacci-
nation cannot be considered cost-effective [7,9]. Though
the four studies focused on either one or both of the
two registered vaccines (RotaTeq®, Merck & Co, Inc,
Whitehouse Station, NJ; and Rotarix®, GlaxoSmithKline
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Biologicals; Rixensart, Belgium), differences in cost-
effectiveness between the vaccines appeared small and
resulted, next to the used vaccination schedules and
genotype-specific efficacy, mainly from assumed
between-dose efficacy estimates. Very recently, new data
from additional trial analyses showed even smaller dif-
ferences in efficacy between both individual vaccines
[11]. We therefore updated the cost-effectiveness ana-
lyses of RV vaccination for the Netherlands assuming
absence of differences between the two vaccines. Two
consensus meetings were held with national and inter-
national experts in the field, from academia, clinical
backgrounds, industry and health policy groups to reach
consensus on final assumptions and resolve any remain-
ing controversies. Explicitly, we investigated the most
important factors in the analyses and those parameters
primarily responsible for the large differences between
the cost-effectiveness estimates of the various models.
Methods
Model
An age-structured cohort model was developed in Excel
for a hypothetical cohort of 180,000 newborns, which
approximates the annual Dutch birth cohort (Figure 1).
A birth cohort is included in the model and two strate-
gies were compared: one being the current situation
without vaccination (current situation), and the other
being mass universal RV vaccination within the frame-
work of the Dutch NIP. The time horizon of the model
was 5 years with time cycles of 1 month for children
less than 1 year of age and annual analysis thereafter.
Outcomes in our analysis were classified by severity and
included home-treated community-acquired diarrhoea
and RV infection leading to consultation of a general
practitioner (GP) and/or hospital admissions (including
emergency department [ED] visits), nosocomial infec-
tions and death. Multiple outcomes per RV infection are
possible in the model, such as the number of GP visits
and hospitalisations.
Epidemiology
Four recent Dutch cost-effectiveness analyses [7-10]
showed a large variation in the incidence of RV despite
the fact that the investigators based their epidemiologi-
cal estimates on similar sources [12-15]. In particular,
the incidence of community-acquired infections result-
ing in a GP visit differed considerably, which was related
to different assumptions regarding underreporting and
extrapolation of the relatively outdated incidence data to
the present. Due to the absence of more recent data, we
chose to include the conservative incidence numbers
based on the recent analysis by Mangen et al. [9]. These
authors made their epidemiological estimations on the
basis of a re-analysis of raw data from previous epide-
miological studies [13,14]. In Table 1, the incidence of
specific categories of RVGE-cases (e.g. number of cases
treated at home, GP visits, and hospitalisations) is
shown for children aged less than 5 years.
In order to calculate age-specific disease distributions
we applied the age-specific hospitalisation distribution
Figure 1 Schematic overview of the model. The boxes represent nodes, with blue squares indicating decision nodes, with green circles
indicating probabilistic nodes and red triangles indicating end nodes. The “No vaccination” arm is a clone of the “Vaccination” arm (as
represented by the + sign).
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Table 1 Parameters used in the economic model
Description Base case
value
Distribution References
Vaccine Efficacy
Severe infections hospitalisation (first year) 0.945 Lognormal mean 0.945 (SE 0.014) [21]
Waning rate per year (exponential decrease) 0 NA [23]
Mild infections requiring an office visit (average first 2
years, see Methods)
0.874 Lognormal mean 0.874 (SE 0.052) [24]
Waning rate per year (exponential decrease) 0.09 NA Assumption
Mild infections treated at home (first year) 0.720 Lognormal mean 0.720 (SE 0.040) [21]
Waning rate per year (exponential decrease) 0.18 NA [21]
Incidence per million children (<5 years)
Total number of community-acquired RV cases 65,680 Normalised mean: 65,680 (90%CI; 43,890-90,945)a [9]
No medical help requested 52,947 Total number of cases minus total number of GP
visits (calculated)
GP visits 12,733 Normalised mean: 12,733 (90%CI; 6,922-20,384)a [9]
Total hospitalisations 3600 Pert (2600; 3600; 4500) [9]
Of which nosocomial infections 13% NA [16]
Deaths as% of total number of hospitalisations 0.02% Triangular (0%; 0.02%; 0.12%) [18]
Total QALY detriment
Rotavirus infection treated at home [25,26]
0-18 months 0.0015 See Methods section
18-59 months 0.0025
Rotavirus infection requiring medical attention (GP) [25,26]
0-18 months 0.0022
18-59 months 0.0031 See Methods section
Rotavirus infection requiring hospitalisation (including
nosocomial)
[25,26]
0-18 months 0.0036 See Methods section
18-59 months 0.0042
Total direct costs per case
Case treated at home (0-3 years)b 4.25 Triangular (2.66; 4.25; 7.44) [7]
Case requiring GP visitb 70.08 Triangular (52.08; 70.08; 82.70) [7,28]
Case requiring hospitalisation 2146 Triangular (1933; 2146; 2359) [7,16,42]
Case requiring hospitalisation (nosocomial) 1825 Triangular (1280; 1825; 2377) [7]
Total indirect cost per case (care giver taking care of child)
Case treated at home 35.26 Triangular (31.74; 35.26; 38.79) [28,42]
Case requiring GP visit 51.09 Triangular (45.99; 51.09; 59.20) [28,42]
Case requiring hospitalisationc 55.41 Triangular (49.87; 55.41; 60.95) [28,42]
Case requiring hospitalisation (nosocomial) 45.34 Triangular (40.80; 45.34; 49.87) [28,42]
Total cost per vaccinee 50, 75, 100 Triangular (50; 75; 100) Assumption
NA, not applicable; SE, standard error
a Square root transformation was applied.
b Cost for older children were lower as diapers were not assumed to be used any more in children aged 3 years and older.
c In the model indirect costs and QALYs are corrected for indirect costs and QALYs which have already occurred at the GP to avoid double counting (as we
assumed that all hospitalised cases would already have visited a GP before being hospitalised).
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which divided the total estimated number of cases by
the different age groups [16]. It was therefore implicitly
assumed that this distribution would be comparable for
hospitalisations, GP visits and cases treated at home. As
the distribution for the nosocomial infections substan-
tially differs from community-acquired RV infection
[17], the age-distribution for nosocomial infections was
based on specific Dutch nosocomial admission data [16].
We assumed that fatal infections would only occur in
hospitalised children. As specific Dutch mortality data is
lacking, we applied a mortality rate of 0.02% for hospita-
lised children based on the hospitalised mortality rate
due to RV infection (as primary diagnosis) observed in
England and Wales [18]. Similar estimates were recently
found for other Western European countries [19,20].
These estimates are all much lower than those used in
the previous Dutch cost-effectiveness studies [7-10].
Vaccine efficacy, waning immunity and between-dose
efficacy
We matched the specific types of disease cases with the
most appropriate vaccine efficacy estimates, preferably
based on clinical trial data gathered in European coun-
tries rather than from other continents. For cases result-
ing in a GP visit or a hospitalisation, efficacy was based
on the observed reductions in health care use in the
trials, while efficacy against cases treated at home was
based on that shown against RVGE cases of any severity.
The vaccine efficacy against RVGE cases treated at
home was recently estimated to be 72.0% (95% confi-
dence interval [CI] 63.2%-78.9%) during the first full
season after vaccination and 58.5% (95%CI 40.1%-74.4%)
during the second full season [21]. Based on the differ-
ence in efficacy between first and second RV seasons
after vaccination, we conservatively assumed that the
vaccine efficacy would exponentially decrease by 18.8%
per year starting after the first year [21].
Against hospitalisation we applied an efficacy of 94.5%
(95%CI: 91.3%-96.8%) based on the rate reduction in
hospitalisations and ED visits observed in European chil-
dren [21]. Based on data for the first 3 years, we
assumed that this efficacy would remain stable during
the first 5 years and thus no waning immunity was
assumed [22]. This assumption is further supported by a
recent study which shows that the efficacy against hos-
pitalisations and ED visits was similar in the first and
second year after vaccination [23]. Efficacy against cases
requiring a GP visit was shown to be 87.4% (95%CI:
75.5%-95.7%) up to 2 years after vaccination [24]. As no
specific waning data are available for this case definition,
we assumed that the waning rate would be 9.4%, which
is the mid-point of the more severe cases (hospitalised)
and mild cases (treated at home). To be consistent, we
increased the first-year efficacy to 90.7% so that the
average vaccine efficacy over 2 years would be equal to
87.4%. We note that in reality, waning might be much
lower (see below), therefore the impact of reducing the
waning rate was also explored.
Previous analyses on cost-effectiveness assumed
slightly lower between-dose efficacies for RotaTeq®
compared to Rotarix®, resulting in a more unfavourable
cost-effectiveness estimate for RotaTeq® [8,9]. However,
recent data suggest that between-dose efficacies for
infections resulting in ED and hospitalisation visits is
much higher for RotaTeq® than was previously assumed
[11]. The efficacy of RotaTeq® against hospitalisations
and/or ED visits between dose 1 and dose 2 was esti-
mated to be 82% (95%CI: 39-97%), and 88% (95%CI: 68-
96%) between dose 2 and dose 3 [11]. This corresponds
to an efficacy proportion after the first dose of 86% (82/
95*100%) and 92% (88/95*100%) between the second
and the third dose. We also applied these proportions
for the between-dose efficacies for infection requiring a
GP visit and cases treated at home.
A vaccine uptake rate of 95% was applied, which
means that in our model, 95% of all children receive all
doses and 5% do not get any doses. The 95% of children
receiving all doses were assumed to be vaccinated at 2,
3 and 4 months.
QALY losses
Two studies estimating health-related quality-of-life
losses in children suffering from RVGE have been per-
formed [25,26]. A recent study in the UK estimated the
quality of life in young children up to the age of 5 with
RVGE using the EQ-5D [26], with 25 GPs as proxies.
The study differentiated according to disease severity
(primary care request only or hospitalisation) and age
(0-18 months; 18 months to 5 years). Goossens et al.
used these estimates in their cost-effectiveness analysis
of RV vaccination [7]. However, most of the RV cost-
effectiveness analysis studies used the quality-adjusted
life year (QALY) weights derived by Brisson et al. [25].
In this Canadian study, caregivers evaluated health-
related quality of life in their children and themselves.
Children (<36 months) and caregivers were included
from 59 participating practices (both family physicians
and paediatricians) when presenting with RVGE [25].
The study estimated the QALY loss in children suffer-
ing from RVGE at 0.0022. No differentiation between
disease severity or age was made. As no data are avail-
able, most previous health economic studies used this
QALY decrease for cases needing medical attention
(both GP and hospitalisation), and reduced it by 50%
for cases requiring no medical help. This approach
might be too conservative for hospitalised cases, since
case inclusion took place when visiting primary care
(although some cases might also have been referred to a
Rozenbaum et al. BMC Public Health 2011, 11:462
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hospital). Furthermore, in case of the Netherlands, the
QALY decrement previously used for cases treated at
home is likely to be too conservative since only the
most severe RVGE cases are expected to visit a primary
care facility in the Netherlands (possibly related to the
fact that no medical certificate is required for staying at
home to care for a sick child and thus caregivers do not
feel the need to visit the GP except for the most severe
cases).
To be conservative, we based our QALY estimates on
the Canadian study, but applied a correction factor for
age and severity (hospitalised cases) on the basis of the
UK study (see Table 1 for specific QALY decrements).
For cases requiring no medical help, we assumed that
the QALY loss would be 31% lower than for cases
requiring a GP visit. This was based on the relative
duration of illness for cases visiting a GP being 7.1 days
and cases treated at home being 4.9 days [9,27]. We
note however that this estimate is still likely to be too
conservative, especially as in the Netherlands.
We did not include QALY decrements for caregivers
in our base-case analysis. However, we did explore the
impact on the incremental cost-effectiveness ratio
(ICER) of including these estimates in a scenario analy-
sis [25]. We also investigated the impact of including
the QALY decrements based on either the Canadian or
the UK estimates, and the impact of including non-age-
or sex weighted disability-adjusted life years (DALYs)
rather than QALYs based on the study by Mangen et al.
[9]. To be conservative and fully in line with the design
of the studies estimating QALY, we only applied one
QALY decrement per RV infection. For example, despite
that probably all hospitalised cases (except for nosoco-
mial cases) would visit the GP before being hospitalised,
only the QALY decrement for hospitalised cases were
included in these cases.
Costs
The analysis was performed from a societal perspective
including both direct costs (health care and non-health
care) and indirect costs of production losses, updated to
2010 (using the consumer price index from The Nether-
lands’ Central Bureau of Statistics). Direct medical costs
included in the analysis were drug costs (also including
over-the-counter medication such as oral rehydration
solutions and paracetamol), prescription fee for the
pharmacist, cost of a GP consultation, and (nosocomial)
hospitalisation costs (see Table 1 for specific costs per
case). Additional costs of diapers and patient travel
costs were included as direct non-medical costs [28].
Productivity losses included absence from work of the
caregiver. Following Kemmeren et al. we assumed that
the average sick leave duration of a caregiver corre-
sponds to 23% of the average illness duration (for more
details see Kemmeren et al.) and that approximately
13% of caregivers would be absent from work to care
for a sick person [28]. Following the Dutch guidelines
for heath economic evaluations we used a productivity
elasticity of 0.8 to take into account compensation
mechanisms for work losses.
In the absence of formal recommendations and reim-
bursement, the cost of the vaccine in the private market
is between €125 and €150 for total vaccination. How-
ever, it is known that when a vaccine is included in the
NIP and bulk quantities are bought by the government,
large price reductions may occur during the tendering
process. Therefore, we decided to calculate the maxi-
mum costs per vaccinated child considering a threshold
of €20,000 and €50,000 per QALY gained based on the
unofficial thresholds that are often applied to the Neth-
erlands [29,30].
Incremental cost-effectiveness calculations
The simulation model tracks cases of specific RVGE
severities (see above), costs, savings and QALYs. Sum-
ming all cases, costs, savings and QALYs and conse-
quently calculating the differences of the respective
outcomes for evaluations with and without vaccination,
rendered averted cases, net costs (costs minus savings)
and QALYs gained. Dividing the net costs by either one
of the health effects defined the ICER. Health effects
(QALYs) and costs were discounted according to the
Dutch guidelines for cost-effectiveness research by 1.5%
and 4.0%, respectively [31].
Sensitivity and scenario analyses
We performed univariate, multivariate and scenario ana-
lyses. As we did not use a fixed cost per vaccinated
child in our analyses, we present the univariate and all
scenario analyses using a total cost of €50, €75 and €100
per vaccinated child. To explore the impact of cost and
utility parameters (other assumptions were varied in
specific scenario analyses) relative to each other, a uni-
variate sensitivity analysis was performed by varying the
value of one parameter by 25%, while the other variables
were kept constant at base-case values (often expected
values of assumed distributions). This was represented
in a Tornado diagram.
Several additional scenarios were considered. Recent
epidemiological studies suggest the existence of herd
protection benefits [32-38]. Also, many so-called
dynamic models have been published which predict a
herd effect in unvaccinated children [39,40]. Based on
these studies, we explored the impact of inclusion of
herd protection benefits for children (up to the age of 5
years) in the cohort. In this scenario we assumed herd
protection for those not yet (fully) protected by the vac-
cine (either too young to be vaccinated or those who
Rozenbaum et al. BMC Public Health 2011, 11:462
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had not yet received the complete set of doses) and
non-vaccinated children (5% of a birth cohort for the
Dutch situation), assuming protection would be as effec-
tive as the vaccination would be after completing all
doses.
Several previous cost-effectiveness analyses have incor-
porated QALY decrements for caregivers assuming their
quality of life would be affected due to the fact that
their children are ill [8,19]. When included, we assumed
a decrement of 0.00184 or 0.0013 (= 0.00184 * 69%) for
caregivers having a child requiring medical attention or
for a case requiring no medical attention (child treated
at home), respectively [8,25]. As noted above, in the
base-case analysis we assumed that QALY decrement
for cases treated at home would be 31% lower than
cases requiring a GP visit based on the respective dura-
tions of illness. As this assumption might still be too
conservative, we also explored the impact of applying a
higher QALY loss for cases treated at home, which was
similar to the QALY loss of cases treated by the GP. On
the other extreme, we also explored a scenario in which
no QALY losses were assumed for cases treated at
home.
In the base-case analysis we used recent data provided
by Mangen et al. for our epidemiological estimates [9].
An older study by Goossens et al. showed similar esti-
mates with the exception of the incidence of RVGE-
related GP visits which was more than twice as high [7].
We explored the impact of this higher GP incidence on
the ICER.
We also investigated the impact of increasing the
assumed mortality rate, based on earlier Dutch analyses
which used much higher mortality rates. Mangen et al.,
for example, used a mortality rate between 0.08% - 0.1%
based on mortality rates observed in New York, USA
[35]. We therefore investigated the impact of a mortality
rate of 0.09% based on this study [35] and 0.055% which
is in the mid-range of the latter estimate and our base-
case estimate.
The impact of varying the productivity elasticity to
labour time was also explored. Although the Dutch
guidelines recommend a factor of 0.8 within the friction
costing approach applied in the Netherlands, other
international studies have included production losses as
a straightforward multiplication of the wage and absence
of work. On the other hand, it has been suggested that
only 25% to 54% of conventionally included work loss
should be taken into account when the time of absence
is short [41]. Therefore, we investigated the impact of
using elasticities of 100% and 25%. Finally, the impact of
excluding indirect costs was explored as well as the
impact of using other discount rates.
For probabilistic sensitivity analyses, parameters were
generated using Monte Carlo sampling with outcome
values being generated by running the model 5,000
times. Lognormal, normal and triangular distribution
were used (Table 1), except for multinomial probabilities
(in particular, the age-specific disease distribution)
where Dirichlet distributions were assumed. Distribu-
tions for QALY decrements were calculated by applying
the correction factor for age and severity (which were
based on the UK study and was kept constant [26])
while varying the QALY decrement based on the Cana-
dian study [25] assuming a normal distribution (mean of
0.0022; standard error [SE] of 0.00026).
Results
Cost-Effectiveness of RV Vaccination in the Base-Case
Analysis
In the base-case analysis, the model estimates that in
the birth cohort followed, 59,495 RVGE cases would
occur resulting in 11,453 GP visits and 3,238 hospitali-
sations of which 421 are extensions of existing hospital
stays due to nosocomial RV infection. With vaccina-
tion, 34,214 cases of RVGE would be averted corre-
sponding to a total (discounted) QALY gain of 109
(see Table 2).
In addition to the health gains, vaccination also pre-
vents approximately €6.3 million of direct and €1.3 mil-
lion of indirect costs. Applying thresholds for maximum
willingness-to-pay of either €20,000 or €50,000 per
QALY resulted in theoretical maximum total cost of
€57.76 and €77.71 (see Figure 2).
Sensitivity and scenario analyses
Figure 3 displays the results of the univariate sensitivity
analysis (applying a total vaccine cost of €75). Apart
from the total cost of vaccination (not included in the
figure), the most influential parameters were the total
Table 2 Results from the base-case analysis
Without
vaccination
With
vaccinationa
Difference
Casesb 59,495 25,281 34,214
Treated at home 47,622 22,389 25,232
GP visits 11,453 2,786 8,667
Hospitalised
(community acquired)
2,817 353 2,464
Hospitalised
(nosocomial)
421 106 315
Deaths 0.65 0.16 0.48
Total QALYs lostc 173 64 109
Total direct costsa (x1000)c € 7,470 € 1,185 € 6,282
Total indirect costs (x1000) c € 2,193 € 888 € 1,305
a Costs are excluding vaccination costs
b Undiscounted
c Discounted
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Figure 3 Sensitivity analysis assumptions on the base-case cost-effectiveness ratio applying a total cost per vaccinated child of €75.
Parameters were varied by 25%. Black bars show the incremental cost-effectiveness ratio after a 25% decrease in the parameter, whereas grey
bars show the incremental cost-effectiveness ratio after a 25% increase. Only parameters which changed the ICER by more than 1% are
displayed. QALY: quality-adjusted life year; GP: general practitioner.
Figure 2 Threshold analysis for various scenarios. The solid black line shows the incremental cost-effectiveness ratio for the base-case
analysis (no QALY losses for caregivers). The black dashed line show the ICER assuming QALY losses for 1 caregiver. The solid red line and the
red dashed line shows the ICER when QALY losses were based on the UK or Canadian study, respectively [25,26]. Assuming a threshold of
€20,000 or €50,000 per QALY specific threshold costs are €57.75 or €77.10 in the base case, €61.29 or €85.92 when the QALY losses were based
on the UK study, €53.04 or €65.31 when the QALY losses were based on the Canadian study, and €63.39 or €91.23 assuming QALY losses for 1
caregiver.
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direct costs associated with hospitalisation. Other para-
meters did not change the ICER by more than 15%
when they were varied by 25%. The same parameters
were also the main influential parameters for the same
analysis performed using a higher (€100) or lower total
vaccination cost (€50). However, when applying a lower
total vaccine cost, the other costs included in the model
become much more influential while an opposite effect
was observed when a higher cost of vaccination was
used (data not shown).
Figure 2 shows the impact on the ICER of varying the
total cost per vaccinated child for different scenarios.
Assuming that one caregiver would suffer QALY losses
as well when their child was ill or applying QALY losses
based on the UK study only [26], resulted in an increase
of the maximum allowable theoretical cost of vaccina-
tion as compared to the base-case. On the other hand
when utility losses were based solely on the Canadian
study [25], the ICER was less favourable at a similar vac-
cination costs compared to the base-case analysis.
Table 3 shows that if vaccination led to indirect pro-
tective effects of unvaccinated individuals less than 5
years of age, the cost-effectiveness would greatly
improve, and even become potentially cost-saving
depending on the total cost of vaccination. Also, there
was a large decrease in the ICER when a higher mortal-
ity rate was applied, when the incidence of GP visits was
based on estimates by Goossens et al. [7], or QALY
losses of children treated at home were assumed to be
similar to those for children treated by the GP. In addi-
tion, the impact of changing the discount rates was con-
siderable, for example, the ICER increased by 8-11%
when an equal discount rate of 3.5% for costs and health
effects was applied and decreased by 16-39% when
neither costs nor effects were discounted. The scenario
which resulted in the least favourable ICER was that
when no QALY decrements were assumed in children
treated at home.
Figure 4 shows the cost-effectiveness acceptability
curves for the same scenarios, resulting from the thresh-
old analysis. This figure shows that in the base-case ana-
lyses, 14% of the simulations resulted in an ICER of less
than €20,000 per QALY. When a threshold of €50,000
per QALY was applied, 74% of the simulations resulted
in acceptable ICERs. In all, but one of the remaining
scenarios more than 70% of the simulations resulted in
an ICER below €50,000 per QALY. When QALY esti-
mates were based solely on the Canadian study [26],
only 47% of the simulations resulted in an ICER below
€50,000 per QALY.
Discussion and conclusions
Our economic analysis indicates that inclusion of RV
vaccination in the Dutch NIP could be considered cost-
Table 3 Scenario analyses
Scenario ICER in €/QALY Total
vaccination cost of €50
ICER in €/QALY Total
vaccination cost of €75
ICER in €/QALY Total
vaccination cost of €100
Base case 7,965 46,717 85,468
Inclusion of herd protection for children up to 5
years of agea
CS 28,383 58,441
GP incidence based on Goossens et al. [7] 498 35,855 71,211
DALYs based on Mangen et al. [9] 7,645 44,841 82,037
QALY decrements in children treated at home
similar to cases visiting a GP
5,823 34,156 62,489
No QALY decrements in children treated at
home
15,172 88,991 162,809
No waning 4,117 37,503 70,888
Mortality rate for hospitalised cases of 0.09% 4,627 27,140 49,653
Mortality rate for hospitalised cases of 0.055% 5,854 34,334 62,813
Productivity elasticity of 25% 16,184 54,936 93,688
No productivity elasticity 4,976 43,728 82,480
Excluding indirect costs (productivity losses) 19,921 58,672 97,424
No discounting 4,846 38,419 71,992
Equal discounting at 3.5% 8,587 51,892 95,197
CS = cost saving
a Herd protection was assumed for those not yet (fully) protected by the vaccine (either too young to be vaccinated or those who had not yet received the
complete set of doses) and non-vaccinated children (5% of a birth cohort for the Dutch situation), assuming protection would be as effective as the vaccination
would be after completing all doses.
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effective depending on the exact cost of the vaccine and
the impact of RV on children’s quality of life. Assump-
tions which have a major impact on the ICER and
which are also associated with a relatively large degree
of uncertainty are (i) the QALY losses associated with
RVGE, particularly in children treated at home and in
caregivers, (ii) inclusion of potential herd protection,
and (iii) the mortality rate in hospitalised RVGE cases.
Along with assumed differences in underreporting, these
aspects also explain the variation in the outcomes of the
cost-effectiveness analyses performed by other research
groups.
Strengths and weaknesses
In the base-case analysis, we chose not to include indir-
ect protective effects for unvaccinated individuals within
(approximately 5% in the Netherlands) and outside the
vaccinated cohort. Recent epidemiological studies do,
however, provide some evidence for the existence of
such herd protection benefits [32-38]. Additionally, sev-
eral so-called dynamic models have been published
which also predict an indirect protective effect in unvac-
cinated children [39,40]. However, further evidence is
required before definite interpretations can be made.
Therefore, we did not include these indirect protective
effects in our base-case analysis as we did not want to
present a too optimistic picture on the cost-effective-
ness, which has been the case previously with pneumo-
coccal vaccination [29,30]. Yet, conservative inclusion of
limited potential herd protection effects in children
(those aged less than 5 years of age) could improve
cost-effectiveness considerably.
QALY losses of caregivers were not included in the
base-case analysis. The impacts on the quality of life of
caregivers are generally not included in Dutch cost-
effectiveness evaluations, and including them here
would have made a comparison with other interventions
difficult (see below). Nevertheless, the Dutch pharma-
coeconomic guidelines indicate that from a societal per-
spective, all costs and benefits should be considered,
irrespective of who pays or loses, and who benefits [42].
This would certainly provide an argument in favour of
including all QALY impacts, such as those on caregivers.
If we did incorporate QALY losses of caregivers, the
ICER decreased considerably. It is not unlikely that a
child suffering from RV has a similar QALY impact on
both parents, and including two caregivers in the analy-
sis could even be advocated. However, given that not all
families consist of two caregivers and our approach is to
remain conservative, this analysis was not pursued here.
Besides the assumed QALY decrements for caregivers,
especially the assumed QALY losses for children treated
at home had a major impact on the ICER. We based
our QALY decrement for children on two published
studies performed in the UK and Canada - the only
ones currently available in the literature [25,26]. In the
UK study, the utility of infants suffering from an RV
infection was determined by health care providers, while
in the Canadian study the utility decrements were esti-
mated by the caregivers of children visiting a GP or
Figure 4 Cost-effectiveness acceptability curves for base-case analysis and several other scenarios.
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paediatrician because of RVGE. Which of these esti-
mates is more appropriate is not easy to determine. The
Canadian study based their estimates on parents, which
might be more suitable when performing a cost-effec-
tiveness study from a societal perspective than estimates
from GPs. On the other hand, the UK study provided
age- and disease-severity-specific estimates, which might
be more appropriate than one overall QALY decrement.
We therefore chose to base our estimates on combining
both studies (as described in the Methods). We do,
however, note that combining the data from these dif-
ferent studies come with limitations. For example, the
utility estimates and the duration of illness, which were
used to estimate the QALY loss per case came from dif-
ferent foreign countries where one would ideally wanted
to have those from one and the same study. Given dif-
ferences in health-care systems and treatment patterns,
combining information on duration and utilities from
different countries may provide non-optimal
estimations.
In contrast to previous studies, which used 50% of the
QALY loss of cases attending primary care for cases not
seeking medical care having, we assumed that the
QALY loss in cases that would be treated at home
would be 31% lower than for cases requiring a GP visit,
based on illness durations. However, we feel that the
former approach is likely to underestimate the QALY
loss in these cases as only the most severe RVGE cases
are expected to visit a primary care facility in the Neth-
erlands (see also below). Although we are aware of the
limitation of our approach, we do feel that this is the
best approach. To anticipate on the uncertainty, we per-
formed extensive sensitivity analyses on the QALY
losses per case not seeking medical care.
We based the mortality rate (0.02% in hospitalised
cases) on a study performed in England and Wales
[18]. Applying this rate in our model resulted in 0.65
deaths for all children less than 5 years of age (assum-
ing a birth cohort of 180,000 infants each year).
Increasing the mortality rates to 0.055% or 0.09%
decreased the ICER to 27% and 42%, respectively.
When we applied higher mortality rates, changes in the
discount rate for health effects had a larger impact on
the ICER, since the life years were obtained over a long
time period.
The GP incidence used in our study is lower com-
pared to those observed and used in other countries. As
previously argued by Mangen et al. this is likely to be
related to the fact that in the Netherlands it is common
practice to advise persons with GE to consult a GP only
if symptoms remain for a longer period, or if the
patient’s health state gets worse [9]. Furthermore, in the
Netherlands it is not required to obtain a medical certi-
ficates from a GP to prove sickness or having a sick
child at home. In other European countries like Ger-
many, France and Spain such a certificate is required
within 1-3 days off work in order to take care of a sick
person, consequently GP’s in these countries will be
consulted more often [9].
In contrast to previous studies, we based our efficacy
estimates on specific European vaccine efficacy data
wherever possible [21,23,24]. Using these data instead of
the general efficacy data (which were based on 11 coun-
tries throughout the world) probably gives more reliable
estimates. We used efficacy estimates based on the lat-
est available data for RotaTeq®. These data show that
the efficacy estimates after the second dose of RotaTeq®
are much more similar to the efficacy of Rotarix® after
the second dose than previously assumed [11]. Also,
remaining differences between both vaccines’ efficacy
estimates are based on clinical trials performed in dif-
ferent regions of the world and case definitions for dis-
ease were different between clinical trials performed
with Rotateq® and Rotarix® [19]. Strictly considered,
our analysis - building on Rotateq® clinical trials - is an
economic evaluation for that specific vaccine, yet we
expect the results for a Rotarix®-specific analysis to be
highly similar given the similarities between both
vaccines.
Comparison with other studies
Our calculated cost-effectiveness ratio for RV vaccina-
tion is in between the estimates of previous Dutch stu-
dies [7-10]. This is due to a combination of factors: (i)
we used a lower total cost per vaccinee, (ii) we used
higher QALY decrements in our study than in three of
the four previous studies [8-10], (iii) we used more rea-
listic disease incidence data (including mortality rates)
compared to all previous studies, and finally (iv) we esti-
mated efficacy based on the most suitable data.
On the one hand, our results indicate that RV vacci-
nation is probably more cost-effective than the current
Dutch pneumococcal vaccination programme with the
seven valent pneumococcal vaccine [30]. On the other
hand, our cost-effectiveness results show that RV vacci-
nation is likely to be more expensive per QALY gained
than other routine vaccination programs recently imple-
mented such as HPV [43] (€30,000 per QALY). It is as
yet unclear how RV vaccination compares to other vac-
cination programs not yet implemented in the Nether-
lands, such as for varicella [44]. Yet, the cost-
effectiveness crucially depends on the exact vaccination
costs of the RV vaccine if included within the Dutch
NIP.
Implications and future research
Increasingly crowded infant vaccination schedules and
restrained national budgets highlight the importance of
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cost-effectiveness analyses in the decision-making pro-
cess on which vaccines should be included in national
immunisation programmes. We show that RV vaccina-
tion in the Netherlands can be considered cost-effective
depending on the total cost per vaccinated child. We
also describe the main drivers for cost-effectiveness out-
comes. In order to make an accurate appraisal of the
RV vaccine and other currently available - but not yet
introduced - vaccines as well as upcoming vaccines such
as respiratory syncytial virus (RSV) vaccines, more accu-
rate data regarding the main uncertain cost-effectiveness
drivers are necessary.
Future research should, therefore, focus in particular
on the number of deaths due to RV infections in the
Netherlands as accurate data for the Netherlands and
most other European countries are currently lacking. In
addition, the relatively old cohort studies conducted at
the population and GP level [12-15] should ideally be
updated, in combination with a cohort study conducted
at hospital level. Furthermore, more research is needed
on the quality of life of infected children. Consensus
should be obtained regarding the question whether or
not to incorporate the effect of childhood disease on the
quality of life of caregivers [19]. Finally, as potential herd
effects have a large impact on the cost-effectiveness, con-
tinued surveillance and additional epidemiological studies
in those countries in which an RV vaccination schedule
has already been introduced should provide more
insights into the epidemiology of RV over time, including
such potential indirect effects.
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